Analyst Price Target is $7.00
▲ +593.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CNS Pharmaceuticals in the last 3 months. The average price target is $7.00, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 593.07% upside from the last price of $1.01.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in CNS Pharmaceuticals. This rating has held steady since January 2021, when it changed from a Hold consensus rating.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.